Presentation: Optimizing the Quantitation of Rifampicin and Pretomanid in Human Plasma by LC-MSMS
March 05, 2026
The first-line anti-TB drug rifampicin poses challenges during method development such as cross-talk with the internal standard, and autooxidation to rifampicin quinone. Pretomanid is a second-line anti-tuberculosis drug, used to treat multi-drug-resistant tuberculosis in combination with other drugs. A method was optimized for the quantitation of these two drugs, working towards the goal of a method that can be used to quantitate several of the most commonly administered anti-TB drugs. Method development and optimization included ascorbic acid supplementation to reverse oxidation as well as use of a rifampicin-d3 isotope for quantitation to prevent cross-talk. The method was successfully validated for simultaneous quantitation of rifampicin ranging from 100-25,000 ng/mL (up to 50,000 ng/mL upon dilution) for rifampicin and 10-10,000 ng/mL (up to 20,000 ng/mL upon dilution) for pretomanid.
Presented at: International Workshop on Clinical Pharmacology of Tuberculosis Drugs July 8 & 9, 2025
